URGN Q4 2018 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$918M

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$24M

Net Income

-$24M

EPS (Diluted)

$-1.46

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$104M

Total Liabilities

$13M

Stockholders' Equity

$90M

Cash & Equivalents

$101M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$327,000	-100.0%
Gross Profit	$0	$40,000	-100.0%
Operating Income	-$24M	-$10M	-136.4%
Net Income	-$24M	-$10M	-135.6%